Abstract
Although oral drug therapy for tuberculosis exists and is widely followed, its major drawbacks are lack of patient compliance and development of adverse effects like hepatotoxicity on long term use. Absence of new therapeutic agents and the above mentioned demerits have led to search for alternative methods for delivery of antitubercular agents. Colloidal drug carriers, a popularly utilized delivery system has been deeply explored for the cause. The article discusses the advances in the management of tuberculosis by the use of particulate and vesicular drug carriers by parenteral, inhalational and oral routes. Use of this delivery strategy has led to massive reduction in the dosage resulting in toxicity alleviation. As a number of studies have already been undertaken in experimental models, it will be a promising tool in the prevention of relapse and successful treatment of tuberculosis in patients.
Keywords: antitubercular drugs, pulmonary tuberculosis, liposomes, niosomes, microspheres, nanoparticles, parenteral, inhalational and oral therapy, patient compliance
Current Drug Delivery
Title: Particulate and Vesicular Drug Carriers in the Management of Tuberculosis
Volume: 3 Issue: 1
Author(s): Rachna Rastogi, Yasmin Sultana, Asgar Ali and Mohammed Aqil
Affiliation:
Keywords: antitubercular drugs, pulmonary tuberculosis, liposomes, niosomes, microspheres, nanoparticles, parenteral, inhalational and oral therapy, patient compliance
Abstract: Although oral drug therapy for tuberculosis exists and is widely followed, its major drawbacks are lack of patient compliance and development of adverse effects like hepatotoxicity on long term use. Absence of new therapeutic agents and the above mentioned demerits have led to search for alternative methods for delivery of antitubercular agents. Colloidal drug carriers, a popularly utilized delivery system has been deeply explored for the cause. The article discusses the advances in the management of tuberculosis by the use of particulate and vesicular drug carriers by parenteral, inhalational and oral routes. Use of this delivery strategy has led to massive reduction in the dosage resulting in toxicity alleviation. As a number of studies have already been undertaken in experimental models, it will be a promising tool in the prevention of relapse and successful treatment of tuberculosis in patients.
Export Options
About this article
Cite this article as:
Rastogi Rachna, Sultana Yasmin, Ali Asgar and Aqil Mohammed, Particulate and Vesicular Drug Carriers in the Management of Tuberculosis, Current Drug Delivery 2006; 3 (1) . https://dx.doi.org/10.2174/156720106775197448
DOI https://dx.doi.org/10.2174/156720106775197448 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modeling Anti-Allergic Natural Compounds by Molecular Topology
Combinatorial Chemistry & High Throughput Screening Structure-Activity Relationships of N-benzylsalicylamides for Inhibition of Photosynthetic Electron Transport
Medicinal Chemistry Radziszewski Reaction: An Elegant, Easy, Simple and Efficient Method to Synthesise Imidazoles
Current Organic Synthesis QSAR Models for Anti-Malarial Activity of 4-Aminoquinolines
Current Computer-Aided Drug Design Pharmacologic Role of Vitamin D Natural Products
Current Vascular Pharmacology Synthesis and Antimycobacterial Activity of 3-(Arylaminomethyl)-5- (Pyridin-4-yl)-1,3,4-Oxadiazole-(3H)-thi-2-One Derivatives Against <i>Mycobacterium Tuberculosis</i> H37rv Strain
Current Bioactive Compounds Design, Synthesis and Biological Evaluation of Carbazole Derivatives as Antitubercular and Antibacterial Agents
Current Bioactive Compounds Thioridazine: Alternative and Potentially Effective Therapy of the XDRTB Patient
Letters in Drug Design & Discovery Targeting Pattern Recognition Receptors (PRRs) in Nano- Adjuvants: Current Perspectives
Current Bionanotechnology (Discontinued) Biomarkers in the Evaluation and Management of Idiopathic Pulmonary Fibrosis
Current Topics in Medicinal Chemistry Review of Common Sequence Alignment Methods: Clues to Enhance Reliability
Current Genomics Immunotherapeutic Targeting of Allergic Disease
Inflammation & Allergy - Drug Targets (Discontinued) Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy Screening for Novel Antituberculosis Agents that are Effective Against Multidrug Resistant Tuberculosis
Current Topics in Medicinal Chemistry Antibacterial Action of Mixed-ligand Imidazole - Phenanthroline Copper Complex
Anti-Infective Agents Strategic Paradigm Shifts in the Antimicrobial Drug Discovery Process of the 21st Century
Infectious Disorders - Drug Targets Persistent Clinical Response of Infliximab Therapy in Patients with Refractory Rheumatoid Arthritis, over a 3-Year Period
Current Clinical Pharmacology New Anti-Tuberculosis Drugs with Novel Mechanisms of Action
Current Medicinal Chemistry TB Diagnostics – Old and New
Current Respiratory Medicine Reviews Protein-protein Interfaces Integrated into Interaction Networks: Implications on Drug Design
Current Pharmaceutical Design